Drug profile · INN
crinecerfont
CRENESSITY
crinecerfont (CRENESSITY) is a corticotropin releasing factor receptor 1 antagonist. Associated with NEUROCRINE BIOSCIENCES INC. Route of administration: oral. Current US regulatory status: approved.
Drug details — crinecerfont
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 8
- Programs
- 4
- Data quality
- 0.89
Quick answer
crinecerfont (CRENESSITY) is a corticotropin releasing factor receptor 1 antagonist. Associated with NEUROCRINE BIOSCIENCES INC. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Corticotropin releasing factor receptor 1 antagonist
Primary target: Corticotropin-releasing factor receptor 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related patents
-
US 12421193
GPR52 modulators and methods of use
granted -
US 12128033
Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine
granted -
US 11730739
Treatment of congenital adrenal hyperplasia
granted -
US 11311544
Treatment of congenital adrenal hyperplasia
granted -
US 10905690
Treatment of congenital adrenal hyperplasia
granted -
US 6469166
Thiophenopyrimidines
expired -
US 6288060
Amino substituted pyrimidines and triazines
expired -
US 6255310
Thiophenopyrimidines
expired
Frequently asked questions
What is crinecerfont?
crinecerfont (CRENESSITY) is a corticotropin releasing factor receptor 1 antagonist. Associated with NEUROCRINE BIOSCIENCES INC. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for crinecerfont?
CRENESSITY is a marketed brand name for crinecerfont. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of crinecerfont?
crinecerfont has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.